Health

Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801

BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies,today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the u...

2025-11-04 21:15 1275

LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction

BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...

2025-11-04 20:04 1824

Sky Labs Attracts Investment With Omron Subsidiary 'OMRON VENTURES'

Global blood pressure monitoring No. 1 OMRON Healthcare signs strategic partnership MoU SEOUL, South Korea, Nov. 4, 2025 /PRNewswire/ -- On November 4, 2025, Sky Labs announced that it had attracted investments with OMRON Ventures(OVC: Minato-ku, Tokyo), Omron Group's enterprise-led venture capit...

2025-11-04 19:25 853

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ ...

2025-11-03 22:15 1563

Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agree...

2025-11-03 22:00 1506

EmeTerm Wristband Significantly Reduces Postoperative Nausea and Vomiting in Major Orthopedic Surgeries

VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial inThe Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomit...

2025-11-03 22:00 1024

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

* Spin-off finalized within five months following board resolution * Proposal approved in shareholders' meeting with 99.9% support * Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the ...

2025-11-03 20:00 1014

GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRA...

2025-11-03 13:26 904

Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Desi...

2025-11-03 12:12 1031

Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.

SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...

2025-10-31 21:00 2055

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku,Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the in...

2025-10-31 20:00 1504

U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)

* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT®  (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...

2025-10-30 15:28 980

United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the compa...

2025-10-30 13:58 843

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and c...

2025-10-30 09:00 989

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agree...

2025-10-29 17:01 811

What Hebei Can Offer丨Biomedicine and Beyond

SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...

2025-10-29 15:23 834

VUNO Partners with European Firms to Advance DeepCARS® Market Entry in Europe

- Strategic MOU enhances market access and extends reach to over 900 hospitals across the region SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austria...

2025-10-29 09:14 940

Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering")...

2025-10-29 04:15 2065

Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics

BEIJING, Oct. 28, 2025 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. , a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025Festival of Biologics in Basel. Over 2,000 biotech experts from 50 countries attended, witnessin...

2025-10-28 22:47 913

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced...

2025-10-28 22:07 1078
1 ... 3456789 ... 311